[1] |
Ooi MH, Wong SC, Lewthwaite P, et al. Clinical features, diagnosis, and management of human entero-virus 71 infection[J]. Lancet Neurol, 2010, 9: 1097-1105.
|
[2] |
Lin JY, Kung YA, Shih SR. Antivirals and vaccines for Enterovirus A71[J]. J Biomed Sci, 2019, 26: 1-65.
|
[3] |
Huang SW, Cheng D, Wang JR. Enterovirus A71: virulence, antigenicity, and genetic evolution over the years[J]. J Biomed Sci, 2019, 26: 1-81.
|
[4] |
Sun H, Gao M, Cui D. Molecular characteristics of the VP1 region of enterovirus 71 strains in China[J]. Gut Pathog, 2020, 12:1-38.
|
[5] |
Brown BA, Oberste MS, Alexander JP, et al. Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998[J]. J Virol, 1999, 73:9969-7995.
|
[6] |
张军楠, 时念民, 罗凤基,等. 肠道病毒71型疫苗交叉保护能力的研究进展[J]. 中国生物制品学杂志, 2015, 28: 648-653.
|
[7] |
Wang X, Peng W, Ren J, et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71[J]. Nat Struct Mol Biol, 2012, 19: 424-429.
|
[8] |
Xu L, He D, Li Z, et al. Protection against Lethal Enterovirus 71 Challenge in Mice by a Recombinant Vaccine Candidate Containing a Broadly Cross-Neutralizing Epitope within the VP2 EF Loop[J]. Theranostics, 2014, 4: 498-513.
|
[9] |
Dang M, Wang X, Wang Q, et al. Molecular mechanism of SCARB2-mediated attachment and uncoating of EV71[J]. Protein Cell, 2014, 5: 692-703.
|
[10] |
Liu CC, Chou AH, Lien SP, et al. Identification and characterization of a cross-neutralization epitope of Enterovirus 71[J]. Vaccine, 2011, 29: 4362-4372.
|
[11] |
Liu CC, Chang HW, Yang G, et al. Development of a quantitative enzyme linked immunosorbent assay for monitoring the Enterovirus 71 vaccine manufacturing process[J]. J Virol Methods, 2011, 176: 60-68.
|
[12] |
Jiang L, Fan R, Sun S, et al. A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice[J]. Vaccine, 2015, 33: 6596-6603.
|